Daniel Kuritzkes
#104,831
Most Influential Person Now
American physician
Daniel Kuritzkes's AcademicInfluence.com Rankings
Daniel Kuritzkesphilosophy Degrees
Philosophy
#6700
World Rank
#9784
Historical Rank
Logic
#3826
World Rank
#5039
Historical Rank
Download Badge
Philosophy
Daniel Kuritzkes's Degrees
- Doctorate Medicine Harvard University
Why Is Daniel Kuritzkes Influential?
(Suggest an Edit or Addition)According to Wikipedia, Daniel Robert Kuritzkes is an American physician. Kuritzkes studied molecular biophysics and biochemistry at Yale University and completed his medical degree at Harvard Medical School. He was trained in internal medicine and infectious diseases at Massachusetts General Hospital and became a visiting scientist at the Whitehead Institute for Biomedical Research prior to joining the University of Colorado Health Sciences Center faculty. Kuritzkes returned to Harvard Medical School in 2002, where he succeeded Elliott D. Kieff as head of the Clinical Infectious Disease Division and the Harriet Ryan Albee Professorship in Medicine.
Daniel Kuritzkes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Update of the Drug Resistance Mutations in HIV-1. (2008) (2026)
- The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
- Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. (2000) (917)
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update (2009) (905)
- Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. (2003) (885)
- Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. (1998) (593)
- SARS-CoV-2 viral load is associated with increased disease severity and mortality (2020) (576)
- Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. (2003) (575)
- Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2008) (569)
- HIV viral load markers in clinical practice (1996) (561)
- Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. (2004) (536)
- Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. (1995) (532)
- Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. (2008) (487)
- Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. (1998) (459)
- International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
- Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation (2014) (368)
- Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. (2011) (349)
- HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance (2007) (335)
- Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response (1997) (289)
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group (1993) (281)
- Drug resistance mutations in HIV-1. (2003) (280)
- Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. (2013) (267)
- Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. (2008) (264)
- Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy (1995) (257)
- Update of the drug resistance mutations in HIV-1: Fall 2005. (2005) (254)
- Update of the drug resistance mutations in HIV-1: Fall 2006. (2006) (250)
- Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. (2007) (249)
- Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. (2006) (241)
- Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo (2009) (239)
- The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption (2015) (235)
- Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. (2006) (235)
- Update of the drug resistance mutations in HIV-1: December 2010. (2010) (234)
- Update of the drug resistance mutations in HIV-1: December 2009. (2008) (231)
- Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. (2014) (230)
- Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease (2002) (224)
- Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. (2010) (215)
- Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity (2001) (213)
- Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. (2010) (210)
- Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir (1998) (210)
- Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2000) (207)
- Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. (2004) (201)
- Infection of the retina by human immunodeficiency virus type I. (1987) (193)
- HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. (2007) (191)
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients (1996) (189)
- Update of the drug resistance mutations in HIV-1: 2007. (2007) (183)
- Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. (2000) (182)
- Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. (1996) (181)
- Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. (2008) (181)
- Integrating microfluidics and lensless imaging for point-of-care testing (2009) (180)
- HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study (2017) (171)
- Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. (2000) (169)
- In vivo analysis of Fas/FasL interactions in HIV-infected patients. (1998) (162)
- Update of the Drug Resistance Mutations in HIV-1: 2005. (2005) (160)
- Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen (2000) (158)
- Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20) (2004) (156)
- Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials (2005) (156)
- HIV-1 entry inhibitors: an overview (2009) (152)
- Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment (1995) (148)
- Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) (2011) (147)
- Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets (2015) (147)
- Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy (2000) (145)
- Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults (2008) (142)
- Update of the drug resistance mutations in HIV-1: Spring 2008. (2008) (142)
- Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement (2014) (140)
- Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. (2012) (139)
- Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370 (2001) (138)
- Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. (2013) (138)
- Accuracy of the TRUGENE HIV-1 Genotyping Kit (2003) (132)
- Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. (2005) (128)
- Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. (2000) (125)
- Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency (2006) (125)
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject (2008) (124)
- Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. (2019) (120)
- Human immunodeficiency virus type 1 protease inhibitors. (1997) (118)
- HIV-1 entry inhibitors: recent development and clinical use. (2013) (118)
- Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis (2006) (116)
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies (2018) (115)
- Vancomycin-resistant gram-positive bacteria isolated from human sources (1988) (115)
- Quantum dot-based HIV capture and imaging in a microfluidic channel. (2009) (114)
- In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA (2005) (111)
- Update of the drug resistance mutations in HIV-1: 2004. (2004) (110)
- Drug resistance mutations in HIV-1. (2003) (108)
- Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. (2000) (107)
- A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors (2009) (107)
- AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. (2010) (105)
- Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. (2011) (104)
- Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome (2001) (103)
- Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. (1999) (100)
- Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial (1998) (100)
- Emerging technologies for point-of-care management of HIV infection. (2015) (99)
- Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy (1996) (96)
- Determination of RNA structural diversity and its role in HIV-1 RNA splicing (2020) (93)
- Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care (2014) (92)
- Adipocyte-Derived Hormone Levels in HIV Lipodystrophy (2003) (90)
- Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. (2013) (89)
- Modeling Long-Term HIV Dynamics and Antiretroviral Response: Effects of Drug Potency, Pharmacokinetics, Adherence, and Drug Resistance (2005) (89)
- High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen (2012) (89)
- In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine (2008) (88)
- Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2016) (86)
- Performance Characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System (2003) (85)
- Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks (2005) (85)
- Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure (2012) (85)
- Workshop on HIV Infection and Aging: What Is Known and Future Research Directions (2008) (84)
- Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. (1999) (83)
- Efficient on-chip isolation of HIV subtypes. (2012) (83)
- Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates (1994) (82)
- Enumeration of CD4+ T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients (2011) (81)
- Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana: Preliminary Results from a Large Randomized Clinical Trial (2007) (81)
- Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure (2011) (79)
- Rapid automated cell quantification on HIV microfluidic devices. (2009) (79)
- Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. (2007) (77)
- Outcomes after virologic failure of first-line ART in South Africa (2010) (77)
- Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study (2018) (75)
- Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. (2015) (74)
- Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. (2007) (73)
- Chemokine antagonists as therapeutics: focus on HIV-1. (2007) (72)
- Clinical significance of drug resistance in HIV‐1 infection (1996) (72)
- Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1 (2011) (72)
- Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1 (2006) (71)
- Use of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB) (1984) (71)
- Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa (2012) (70)
- Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns (2004) (70)
- Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness (2010) (70)
- A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 (2003) (68)
- Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia (2014) (68)
- MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study (2003) (67)
- Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals (2004) (67)
- Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 (2007) (67)
- Second-Line Antiretroviral Therapy: Long-Term Outcomes in South Africa (2012) (66)
- Clinical implications of HIV-1 minority variants. (2013) (65)
- Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. (2010) (64)
- Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone. (2018) (64)
- Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. (2009) (64)
- Simple filter microchip for rapid separation of plasma and viruses from whole blood (2012) (63)
- Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection (2010) (62)
- The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations (2005) (62)
- Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile (2019) (61)
- Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. (1999) (61)
- Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30 (2018) (60)
- Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
- Preventing and managing antiretroviral drug resistance. (2004) (60)
- Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) (2007) (60)
- Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
- HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers (2018) (57)
- Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia (2012) (57)
- Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. (2013) (56)
- Rapid, label-free CD4 testing using a smartphone compatible device. (2017) (56)
- Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics (2015) (55)
- The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. (2010) (55)
- Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. (1998) (54)
- Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. (1999) (54)
- Rate of Thymidine Analogue Resistance Mutation Accumulation With Zidovudine- or Stavudine-Based Regimens (2004) (53)
- Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics (2014) (53)
- Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort (2021) (53)
- Drug resistance in HIV-1. (2011) (51)
- DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics (2018) (51)
- TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. (2007) (51)
- Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. (2013) (50)
- High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay (2017) (49)
- Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine (2013) (49)
- High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection. (1994) (49)
- Altered Viral Fitness of HIV‐1 Following Failure of Protease Inhibitor‐Based Therapy (2000) (48)
- Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens. (2017) (47)
- Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. (2007) (47)
- Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL (2012) (47)
- Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. (2000) (46)
- Virologic and regimen termination surrogate end points in AIDS clinical trials. (2001) (45)
- Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration (2017) (44)
- Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection (2018) (43)
- Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. (2007) (43)
- Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. (2000) (43)
- Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis (2021) (42)
- Hematopoietic stem cell transplantation for HIV cure. (2016) (41)
- Monitoring HIV treatment in developing countries (2006) (41)
- Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. (1996) (40)
- What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection (2004) (40)
- Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia (2011) (40)
- Clinical features and treatment of infection due to mycobacterium fortuitum/chelonae complex. (1993) (40)
- Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. (2013) (40)
- Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy (2014) (38)
- Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2000) (38)
- Pharmacodynamics of Antiretroviral Agents in HIV-1 Infected Patients: Using Viral Dynamic Models that Incorporate Drug Susceptibility and Adherence (2006) (38)
- Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation (2004) (38)
- Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy (2004) (37)
- Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications (2022) (37)
- Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. (1999) (36)
- Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. (2011) (36)
- Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. (2004) (35)
- Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy (2017) (35)
- Challenges in clinical trial design for HIV-1 cure research (2013) (35)
- A Novel Recombinant Marker Virus Assay for Comparing the Relative Fitness of HIV‐1 Reverse Transcriptase Variants (2001) (35)
- Tropism testing in the clinical management of HIV-1 infection (2009) (35)
- Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. (2003) (35)
- Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines (2020) (34)
- Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. (1998) (34)
- Assessing resistance costs of antiretroviral therapies via measures of future drug options. (2003) (34)
- Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. (2010) (34)
- Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. (2005) (34)
- COVID-19 and HIV infection co-pandemics and their impact: a review of the literature (2021) (34)
- Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation (2017) (33)
- HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug (2011) (33)
- Phenotypic and Genotypic Analysis of Biologically Cloned Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Zidovudine and Lamivudine (2002) (32)
- Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study (2014) (32)
- Fat distribution is altered in HIV‐infected men without clinical evidence of the HIV lipodystrophy syndrome (2003) (32)
- Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals (1997) (32)
- HIV-1 subtype as a determinant of disease progression. (2008) (32)
- Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin (2008) (31)
- Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. (2011) (31)
- Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy (2010) (31)
- Escherichia coli mutant with altered respiratory control of the frd operon (1985) (30)
- Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. (1995) (30)
- Cardiovascular risk factors and antiretroviral therapy. (2003) (30)
- Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa (2012) (30)
- Altered Viral Fitness and Drug Susceptibility in HIV-1 Carrying Mutations That Confer Resistance to Nonnucleoside Reverse Transcriptase and Integrase Strand Transfer Inhibitors (2014) (30)
- Treatment-Mediated Alterations in HIV Fitness Preserve CD4+ T Cell Counts but Have Minimal Effects on Viral Load (2010) (29)
- The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. (2010) (29)
- Role of Baseline pol Genotype in HIV-1 Fitness Evolution. (2003) (29)
- A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”? (2016) (29)
- Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva (2015) (29)
- Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection (2005) (29)
- Syncytium formation by recombinant HTLV-II envelope glycoprotein. (1996) (28)
- Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. (1999) (28)
- Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV (2017) (28)
- In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. (1996) (27)
- HIV-1–Infected Antiretroviral-Treated Patients With Prolonged Partial Viral Suppression: Clinical, Virologic, and Immunologic Course (2003) (27)
- Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 &Dgr;32 (2015) (26)
- Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients (2010) (26)
- Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options (2011) (26)
- Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy (2015) (25)
- SARS‐CoV‐2 RNA Detection by a Cellphone‐Based Amplification‐Free System with CRISPR/CAS‐Dependent Enzymatic (CASCADE) Assay (2021) (25)
- Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. (1993) (25)
- Resistance in Pediatric Patients Experiencing Virologic Failure With First-line and Second-line Antiretroviral Therapy (2013) (25)
- Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. (2001) (24)
- Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. (2003) (24)
- Patients Infected with CRF07_BC Have Significantly Lower Viral Loads than Patients with HIV-1 Subtype B: Mechanism and Impact on Disease Progression (2014) (24)
- Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV‐1‐Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy (2000) (24)
- Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate (2010) (24)
- Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients (2011) (23)
- Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. (2012) (23)
- HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. (2009) (23)
- Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. (2013) (23)
- In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. (1998) (23)
- Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy (2007) (23)
- HIV resistance: frequency, testing, mechanisms. (2007) (22)
- Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide (2008) (22)
- A fossil record of zidovudine resistance in transmitted isolates of HIV-1 (2001) (22)
- Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. (2008) (21)
- Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. (2005) (21)
- Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers (2019) (21)
- Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. (1999) (21)
- Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. (2010) (21)
- A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115 (2007) (20)
- Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. (2001) (20)
- Effect of the Q207D Mutation in HIV Type 1 Reverse Transcriptase on Zidovudine Susceptibility and Replicative Fitness (2005) (20)
- Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA (2018) (20)
- Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118) (2005) (20)
- Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. (2017) (20)
- Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child. (1993) (20)
- Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression (2007) (20)
- Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b) (2015) (20)
- Three classes of Escherichia coli mutants selected for aerobic expression of fumarate reductase (1986) (20)
- Hematopoietic cell transplantation and HIV cure: where we are and what next? (2013) (20)
- Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370 (2000) (20)
- Pyomyositis due to group C streptococci in a patient with AIDS. (1991) (19)
- Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials (2016) (19)
- A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. (2001) (19)
- Prevalence and Clinical Associations of CXCR4-Using HIV-1 Among Treatment-Naive Subtype C-Infected Women in Botswana (2011) (19)
- Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life (2020) (19)
- Preventing and Managing Resistance in the Clinical Setting (2003) (19)
- Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. (2000) (18)
- Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study (2013) (18)
- Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. (2009) (18)
- Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). (2005) (17)
- Why cure, why now? (2016) (17)
- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1A Randomized, Controlled Equivalence TrialNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (2014) (17)
- Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants (2016) (17)
- Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing (2016) (17)
- Development of a microfluidic system for measuring HIV-1 viral load (2010) (16)
- SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses (2011) (16)
- Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial (2000) (16)
- Extending antiretroviral therapy to resource-poor settings: implications for drug resistance (2004) (16)
- Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. (2001) (16)
- Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group (ACTG) 5366. (2020) (15)
- Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. (2010) (15)
- Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. (2006) (15)
- Enumeration of CD 4 + T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients (2011) (15)
- Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. (2002) (15)
- Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095 (2005) (15)
- Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. (1999) (15)
- Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions (2022) (14)
- Viral kinetics: implications for treatment. (1999) (14)
- Targeted HIV testing at birth supported by low and predictable mother‐to‐child transmission risk in Botswana (2018) (14)
- ART reduces T cell activation and immune exhaustion markers in HIV controllers. (2019) (14)
- Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. (2020) (14)
- HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. (1999) (14)
- Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases (2011) (14)
- Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. (2000) (14)
- Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. (2008) (13)
- Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images (2021) (12)
- Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019 (2021) (12)
- Resistance to Dolutegravir-A Chink in the Armor? (2018) (12)
- Human immunodeficiency virus. (2009) (11)
- Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations (2006) (11)
- Phylogenetic Evidence of HIV-1 Sequence Evolution in Subjects with Persistent Low-Level Viraemia (2015) (11)
- Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. (2001) (11)
- High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998–2004 (2007) (11)
- Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. (1994) (11)
- Treatment of HIV Infection with a Raltegravir-Based Regimen Increases LDL Levels, but Improves HDL Cholesterol Efflux Capacity (2017) (11)
- Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. (2000) (10)
- Genotypic tests for determining coreceptor usage of HIV-1. (2011) (10)
- Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists (2012) (10)
- Erratum: Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol (Virology (1999) 259:1 (154-165)) (1999) (10)
- Use of lac operon fusions to isolate Escherichia coli mutants with altered expression of the fumarate reductase system in response to substrate and respiratory controls. (1979) (10)
- Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children. (2002) (9)
- Phase 1 study of combination therapy with L-697,661 and zidovudine (1996) (9)
- Immunological and Neurometabolite Changes associated with switch from Efavirenz to an Integrase Inhibitor. (2019) (9)
- Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211) (2010) (9)
- Erratum: HIV type 1 chemokine co-receptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211 (Clinical Infectious Diseases (2007) 44, (591-595)) (2007) (9)
- Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis (2017) (9)
- Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. (1992) (9)
- CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. (2016) (9)
- Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study (2014) (9)
- Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates under Sequential Drug Selection Pressures (2012) (9)
- Drug development strategies for salvage therapy: conflicts and solutions. (2006) (9)
- Evolution of coreceptor utilization to escape CCR5 antagonist therapy (2016) (9)
- Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions (2009) (8)
- Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group (1996) (8)
- Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men. (2016) (8)
- A comparison of three initial antiretroviral AIDS regimens. (2007) (8)
- Detached ciliary tufts mistaken for peritoneal parasites: a warning. (1988) (8)
- Virologic Characterization of HIV Type 1 With a Codon 70 Deletion in Reverse Transcriptase (2007) (8)
- Drug Resistance Testing: Time to be Used in Clinical Practice? (2001) (8)
- Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption (2017) (8)
- Bamlanivimab for Prevention of COVID-19. (2021) (8)
- What risk of death would people take to be cured of HIV and why? A survey of people living with HIV (2019) (8)
- Current management challenges in HIV: antiretroviral resistance. (2003) (8)
- Evaluation of HIV-1 Ambiguous Nucleotide Frequency During Antiretroviral Treatment Interruption (2012) (7)
- Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment (2009) (7)
- A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa (2020) (7)
- Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial (2012) (7)
- Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. (2009) (7)
- Errors in Celia Farber's March 2006 article in Harper's Magazine (2006) (7)
- Impact of pre-existing drug resistance on risk of virological failure in South Africa. (2021) (7)
- Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. (2004) (6)
- Viral Load Kinetics of SARS-CoV-2 In Hospitalized Individuals with COVID-19 (2021) (6)
- Clinical experience with Filgrastim in AIDS. (1999) (6)
- Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV (2021) (6)
- Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility (1990) (6)
- Lensless imaging for point-of-care testing (2009) (6)
- HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States (2016) (6)
- Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. (1999) (6)
- Mother-to-Child HIV Transmission with in utero Dolutegravir vs. Efavirenz in Botswana. (2020) (6)
- Emergence of Dual Resistance to Zidovudine and Lamivudine in Clinical HIV-1 Isolates from Patients Receiving Zidovudine/Lamivudine Combination Therapy (1998) (5)
- A Plea for Justice for Jailed Medical Workers (2006) (5)
- An update on HIV-1 antiretroviral resistance (2006) (5)
- Least among equals. (2012) (5)
- Ethical conduct of research in resource-limited settings. (2004) (5)
- Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression. (2021) (5)
- “Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication (2020) (5)
- Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets (2010) (5)
- Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals (2004) (4)
- Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. (2014) (4)
- The Future of HIV Treatment (2012) (4)
- A graphene-modified cellulose paper microchip for HIV detection (2015) (4)
- Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. (1996) (4)
- Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy (2020) (4)
- Restricted HIV-1 diversity and clonal expansion following cytoreductive chemotherapy (2015) (3)
- Drug resistance. Navigating resistance pathways. (2002) (3)
- Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. (1996) (3)
- Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana (2021) (3)
- Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen (2005) (3)
- Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial). (2022) (3)
- HIV Drug Resistance : New Insight and Updated Practices (2004) (3)
- HAART for HIV-1 infection: zeroing in on when to start: comment on "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters". (2011) (3)
- Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation (2018) (3)
- Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first‐line therapy in South Africa: a case–control cohort study (2021) (3)
- Guidelines for an effective radiation safety program in a human immunodeficiency virus (HIV) laboratory. (1990) (3)
- Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa (2013) (3)
- Evolution of resistance in paediatric patients with failure on antiretroviral therapy (2012) (3)
- Acute HIV detection by viral lysate impedance spectroscopy on a microchip (2013) (3)
- Interleukin-2: trials and tribulations. (2009) (3)
- Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. (2023) (3)
- Domain 4 of ILY sensitizes antibody therapy on cancer and HIV through abrogating human CD59 function (2008) (2)
- Early Intensification with Abacavir in Subjects at High Risk for Incomplete Viral Suppression (2002) (2)
- Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? (2022) (2)
- Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV (2022) (2)
- Switching from Efavirenz to Nevirapine. Authors' reply (2010) (2)
- NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. (2018) (2)
- Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. (2003) (2)
- Emerging nanotechnology approaches for HIV / AIDS treatment & prevention Review (2010) (2)
- Rapid expansion of access to antiretroviral therapy (ART). (2004) (2)
- Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States (2021) (2)
- Nanoplasmonic biosensing platform for multiple pathogen detection (2013) (2)
- Crosstalk between Host Genome and Metabolome among People with HIV in South Africa (2022) (2)
- Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction. (2004) (2)
- Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children (2022) (2)
- Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice. (1995) (2)
- Report from the XVIII International HIV Drug Resistance Workshop. (2007) (2)
- Investigating new antiretroviral combinations. Author's reply (2006) (2)
- 541HIV Rebound Kinetics and CD4+ T-Cell Loss after Treatment Interruption: A Pooled Analysis of Six AIDS Clinical Trials Group (ACTG) Studies (2014) (1)
- Progress in HIV vaccine research: an outsider's view (2012) (1)
- Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa. (2007) (1)
- World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries (2003) (1)
- ThreeClasses ofEscherichia coli Mutants Selected forAerobic Expression ofFumarate Reductase (1986) (1)
- UpdateoftheDrugResistanceMutationsinHIV-1: Spring 2008 (2008) (1)
- Recent developments in HIV-1 drug resistance. (1999) (1)
- Track A Basic Science (2012) (1)
- Report from the XV International HIV Drug Resistance Workshop. (2006) (1)
- Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 (2021) (1)
- Resistance to protease inhibitors. (2002) (1)
- Comparing effectiveness of first‐line antiretroviral therapy between peri‐urban and rural clinics in KwaZulu‐Natal, South Africa (2021) (1)
- Lab‐on‐Chip: Acute On‐Chip HIV Detection Through Label‐Free Electrical Sensing of Viral Nano‐Lysate (Small 15/2013) (2013) (1)
- Effect of antiretroviral resistance on response in treatment-experienced patients. (2003) (1)
- Prevalence of the K65R mutation in subtype C HIV-1-infected subjects failing TDF-containing first-line antiretroviral therapy in south africa using deep sequencing (2014) (1)
- HIV Clinical Trials: Important Concepts and Questions (2005) (1)
- Blinded, multicenter comparison of methods to detect low frequency drug-resistant HIV-1 variants (2006) (1)
- Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2016) (1)
- Immune correlates of HIV-1 reservoir cell decline in early-treated infants (2022) (1)
- HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. (2020) (1)
- Hiv Controllers Maintain Viral Suppression Despite Waning T-Cell Responses On Art. (2020) (1)
- New perspectives on the virologic consequences of M184V or I in HIV-1 Reverse Transcriptase. (2019) (1)
- Drug Therapy in HIV Infection--Ninth International Congress. (2009) (1)
- HIV/AIDS Salvage Therapy (2003) (1)
- Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy (2020) (1)
- An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes". (2012) (1)
- Report from the XVI International HIV Drug Resistance Workshop. (2007) (1)
- Is France Once Again Looking for a Scapegoat? (2021) (1)
- Management of patients with virologic and metabolic failure. (2003) (1)
- Nucleoside Reverse Transcriptase Inhibitors : Resistance , Cross-Resistance , and Resistance Testing (2002) (1)
- Viral Zoonoses (2019) (0)
- Targeting HIV Beyond Protease and Reverse Transcriptase Inhibitors (2001) (0)
- Reply to Bellosillo et al (2009) (0)
- HIV Cure Research Update (2017) (0)
- Lines from HIV-1-Infected Children In Vitro Effects of IL-12 on HIV-1-Specific CTL (2017) (0)
- HIV‐1 proviral landscape characterization varies by pipeline analysis (2021) (0)
- O211: Treatment for HIV: new drugs and strategies (2015) (0)
- The Best Approach to Reintroducing Tuberculosis Treatment after Hepatotoxicity Is Still (2010) (0)
- Determination of RNA structural diversity and its role in HIV-1 RNA splicing (2020) (0)
- Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations (2006) (0)
- Associations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa (2022) (0)
- Likely Possible Unlikely Technical Cut-off Clinical Cut-off Resistance Index Efficient Drug Non Efficient Drug (2003) (0)
- HIV and AIDS (2018) (0)
- Selected Topics from the 8th Conference on Retroviruses and Opportunistic Infections (2001) (0)
- HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
- Antiviral Drug Resistance, Douglas R. Richman (Ed.). John Wiley & Sons (1996) (1998) (0)
- Small differences in CD4+ T-cell production may go unnoticed. (1999) (0)
- Approaching the asymptote. (2022) (0)
- The Sloth (2019) (0)
- Update from the 20th CROI: Pathogenesis, Prevention and Treatment (2013) (0)
- New Issues in HIV Drug Resistance (2008) (0)
- PROGRESS IN HIV-1 PATHOGENESIS AND TREATMENT (2000) (0)
- Author Correction: Determination of RNA structural diversity and its role in HIV-1 RNA splicing (2020) (0)
- Initiatives for developing genotype interpretation systems: derivation and validation of a didanosine interpretation system using large derivation and large validation datasets (2008) (0)
- Alternative options for treatment-experienced people with HIV. (2023) (0)
- Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 (2021) (0)
- Drug Resistance Mutations in HIV-1. (2002) (0)
- Filgrastim (r‐mei‐HuG‐CSF)prevents severe neutropenia & reduces related clinical sequelae in HIV‐infected patients:24week,prospective,randomized,controlled trial results.: 323 (1997) (0)
- Fellows' Day Program (open to fellows only) (2005) (0)
- The ethical case for placebo control in HIV-cure-related studies with ART interruption (2022) (0)
- O115 Importance of detecting minority variants in the clinical management of HIV (2008) (0)
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject (cid:1) † (2008) (0)
- Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA (2023) (0)
- Drug Resistance Working Group. AIDS Clinical Trials Group Virology Committee virus type 1 drug resistance mutation. The reaction to detect a human immunodeficiency sequence-specific PCR and ligase detection Interlaboratory comparison of (2013) (0)
- HIV and AIDS (2018) (0)
- Reply to Gelinck and Burger (2010) (0)
- Comprar Hiv essentials 2011 | Paul E. Sax | 9781449613396 | Jones & Bartlett Publishers (2011) (0)
- Pyomyositis due to catalase-negative organism in patient with AIDS. (1992) (0)
- 38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality (2021) (0)
- Reply to Carr (2006) (0)
- Ultra-deep sequencing of HIV quasi-species to detect minority variants (2010) (0)
- Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV (2017) (0)
- HIV/AIDS salvage therapy. Interview by Vicki Glaser. (2003) (0)
- Estimating reservoir size with uncertainty in viral dynamics parameters (2016) (0)
- PP 4.14 – 00173 Antiretroviral therapy repairs CD4 T cell dysregulation in people living with HIV (2022) (0)
- T Cell Subset Enumeration and Weekend HIV Clinics: Reliable Performance of CD4 Cell Counts after 3 Days (2010) (0)
- POSB12 Association Between Remdesivir Treatment and In-Hospital All-Cause Mortality Among Patients Hospitalized with COVID-19 (2022) (0)
- Viral and Host Mediators of Non-Suppressible HIV-1 Viremia (2023) (0)
- Response to Shen and Siliciano (2010) (0)
- Curing HIV-1 Infection Remains an Elusive Goal (2014) (0)
- What's Hot in HIV (2005) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Long acting cabotegravir and rilpivirine: innovation, new challenges and opportunities. (2023) (0)
- Report from the XVII International HIV Drug Resistance Workshop. (2008) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- next? Hematopoietic cell transplantation and HIV cure: where we are and what (2013) (0)
- Understanding Treatment- Resistant HIV (2003) (0)
- B-102 Status of HIV Cure Research—is there light at the end of the tunnel? (2014) (0)
- HIV cure research: Update from CROI 2016 (2016) (0)
- When to Change HAART: The Role of HIV-1 Resistance Testing (2005) (0)
- Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial (2022) (0)
- When more is less. (2004) (0)
- Antiretroviral Therapy - 2007 (2007) (0)
- Escherichia coli MutantwithAltered Respiratory Control ofthe frdOperon (1985) (0)
- Resistance Testing for HIV (2004) (0)
- DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics (2018) (0)
- Factors associated with viral control after structured treatment interruptions (2019) (0)
- HIV Drug Therapy in the Americas Congress, 13 – 15 June 2013, São Paulo, Brazil (2013) (0)
- Early experience with HSCT in HIV-infected patients (2016) (0)
- In Memoriam: Mark A. Wainberg. (2017) (0)
- Reply to Gelinck and Burger (2010) (0)
- Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. (2014) (0)
- Hot Topics in HIV (2007) (0)
- Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. (2012) (0)
- HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
This paper list is powered by the following services:
Other Resources About Daniel Kuritzkes
What Schools Are Affiliated With Daniel Kuritzkes?
Daniel Kuritzkes is affiliated with the following schools:
